Pennant Group

Aging Population And Home Care Will Expand Market Access

AnalystHighTarget

Not Invested

Consensus Narrative from 5 Analysts

Published

10 Aug 25

Updated

10 Aug 25

AnalystHighTarget's Fair Value

US$40.00

34.8% undervalued

10 Aug

US$26.08

-14.0%

17.2%

Author's Valuation

US$40.0

34.8% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$40.0

34.8% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

12.95%

Healthcare Services revenue growth rate

0.28%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$72.54m

Earnings '28

34.75x

PE Ratio '28

US$2.52b

Market Cap '28

US$2.52b

Market Cap '28

51.77m

No. shares '28

US$48.69

Share Price '28

US$48.69 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$40.00

Fair Value '25